{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T22:07:30Z","timestamp":1763503650065,"version":"3.45.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["162066"],"award-info":[{"award-number":["162066"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Can J Public Health"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.17269\/s41997-025-01056-y","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T10:52:16Z","timestamp":1748947936000},"page":"509-517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The effect of take-home naloxone kits on opioid-related deaths in Alberta, Canada: An ecological analysis"],"prefix":"10.17269","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8558-5973","authenticated-orcid":false,"given":"Eldon","family":"Spackman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shainur","family":"Premji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Woroniuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eddy","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina","family":"Milaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry","family":"McBrien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"1056_CR1","unstructured":"Alberta Community Council on HIV. (2020). A report on the effectiveness of the Community-Based Take Home Naloxone Program. https:\/\/northreach.ca\/wp-content\/uploads\/2020\/06\/2020-05-20-A-Report-on-the-Community-Based-Take-Home-Naloxone-Program-Effectiveness.pdf"},{"key":"1056_CR2","unstructured":"Alberta Government. (2021). Alberta Regional Dashboard. Regional Dashboard. https:\/\/regionaldashboard.alberta.ca\/#\/"},{"key":"1056_CR3","unstructured":"Alberta Health. (2019). Opioid-related deaths in Alberta in 2017: Review of medical examiner data. https:\/\/open.alberta.ca\/publications\/9781460143421"},{"key":"1056_CR4","unstructured":"Alberta Health Services. (2019). Harm reduction services team frequently asked questions for clients. www.ahs.ca\/naloxone"},{"key":"1056_CR5","unstructured":"Alberta Health Services. (2021). Community Based Naloxone Program. Harm Reduction Services. https:\/\/www.albertahealthservices.ca\/info\/Page13663.aspx"},{"key":"1056_CR6","doi-asserted-by":"publisher","unstructured":"Altekruse, S. F., Cosgrove, C. M., Altekruse, W. C., Jenkins, R. A., & Blanco, C. (2020). Socioeconomic risk factors for fatal opioid overdoses in the United States: Findings from the mortality disparities in American communities Study (MDAC). PLoS ONE, 15(1), e0227966. https:\/\/doi.org\/10.1371\/journal.pone.0227966","DOI":"10.1371\/journal.pone.0227966"},{"issue":"5","key":"1056_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/add.13265","volume":"111","author":"SM Bird","year":"2016","unstructured":"Bird, S. M., Mcauley, A., Perry, S., & Hunter, C. (2016). Effectiveness of Scotland\u2019s National Naloxone Programme for reducing opioid-related deaths: A before (2006\u201310) versus after (2011\u201313) comparison. Addiction, 111(5), 883\u2013891. https:\/\/doi.org\/10.1111\/add.13265","journal-title":"Addiction"},{"key":"1056_CR8","doi-asserted-by":"crossref","unstructured":"Broadhurst, R., Ball, M., Jiang, C., Wang, J., & Trivedi, H. (2021). Impact of darknet market seizures on opioid availability | Australian Institute of Criminology. In Research Report no. 18. Canberra: Australian Institute of Criminology. https:\/\/www.aic.gov.au\/publications\/rr\/rr18","DOI":"10.52922\/rr04886"},{"issue":"2","key":"1056_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.25318\/82-003-x202100200003-eng","volume":"32","author":"G Carri\u00e8re","year":"2021","unstructured":"Carri\u00e8re, G., Sanmartin, C., & Garner, R. (2021). Understanding the socioeconomic profile of people who experienced opioid overdoses in British Columbia, 2014 to 2016. Health Reports, 32(2), 27\u201338. https:\/\/doi.org\/10.25318\/82-003-x202100200003-eng","journal-title":"Health Reports"},{"issue":"6","key":"1056_CR10","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/0735-6757(94)90033-7","volume":"12","author":"JM Chamberlain","year":"1994","unstructured":"Chamberlain, J. M., & Klein, B. L. (1994). A comprehensive review of naloxone for the emergency physician. American Journal of Emergency Medicine, 12(6), 650\u2013660. https:\/\/doi.org\/10.1016\/0735-6757(94)90033-7","journal-title":"American Journal of Emergency Medicine"},{"key":"1056_CR11","unstructured":"Coggon, D., Rose, G., & Barker, D. (2002). Ecological studies. In Epidemiology for the uninitiated (5th ed., pp. 39\u201341). BMJ Publishing Group. https:\/\/www.bmj.com\/about-bmj\/resources-readers\/publications\/epidemiology-uninitiated\/6-ecological-studies#chapters"},{"key":"1056_CR12","doi-asserted-by":"publisher","unstructured":"Connery, H. S. (2015). Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions. Harvard Review of Psychiatry, 23 (2), 63\u201375. Lippincott Williams and Wilkins. https:\/\/doi.org\/10.1097\/HRP.0000000000000075","DOI":"10.1097\/HRP.0000000000000075"},{"key":"1056_CR13","doi-asserted-by":"crossref","unstructured":"Correia, S., Guimaraes, P., & Zylkin, T. (2020). Fast Poisson estimation with high-dimensional fixed effects. The Stata Journal, 20(1).","DOI":"10.1177\/1536867X20909691"},{"key":"1056_CR14","doi-asserted-by":"publisher","unstructured":"Degenhardt, L., Reuter, P., Collins, L., & Hall, W. (2005). Evaluating explanations of the Australian \u201cheroin shortage.\u201d Addiction\u00a0(vol. 100, no.\u00a04, pp. 459\u2013469). John Wiley & Sons, Ltd. https:\/\/doi.org\/10.1111\/j.1360-0443.2005.01000.x","DOI":"10.1111\/j.1360-0443.2005.01000.x"},{"issue":"3","key":"1056_CR15","first-page":"219","volume":"12","author":"C Ghelardini","year":"2015","unstructured":"Ghelardini, C., Di Mannelli Cesare, L., & Bianchi, E. (2015). The pharmacological basis of opioids. Clinical Cases in Mineral and Bone Metabolism, 12(3), 219\u2013221.","journal-title":"Clinical Cases in Mineral and Bone Metabolism"},{"issue":"7","key":"1056_CR16","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S2468-2667(19)30060-X","volume":"4","author":"N Gisev","year":"2019","unstructured":"Gisev, N., Bharat, C., Larney, S., Dobbins, T., Weatherburn, D., Hickman, M., Farrell, M., & Degenhardt, L. (2019). The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: A retrospective cohort study. The Lancet Public Health, 4(7), e334\u2013e342. https:\/\/doi.org\/10.1016\/S2468-2667(19)30060-X","journal-title":"The Lancet Public Health"},{"key":"1056_CR17","unstructured":"Government of Canada. (2021). Government of Canada Actions on Opioids: 2016 and 2017. https:\/\/www.canada.ca\/en\/health-canada\/services\/publications\/healthy-living\/actions-opioids-2016-2017.html"},{"key":"1056_CR18","unstructured":"Government of Canada. (2024). Opioid- and Stimulant-related Harms in Canada. https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/"},{"issue":"5","key":"1056_CR19","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S2468-2667(18)30044-6","volume":"3","author":"MA Irvine","year":"2018","unstructured":"Irvine, M. A., Buxton, J. A., Otterstatter, M., Balshaw, R., Gustafson, R., Tyndall, M., Kendall, P., Kerr, T., Gilbert, M., & Coombs, D. (2018). Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: A modelling study. The Lancet Public Health, 3(5), e218\u2013e225. https:\/\/doi.org\/10.1016\/S2468-2667(18)30044-6","journal-title":"The Lancet Public Health"},{"issue":"1","key":"1056_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1151\/spp021113","volume":"1","author":"TR Kosten","year":"2002","unstructured":"Kosten, T. R., & George, T. P. (2002). The neurobiology of opioid dependence: Implications for treatment. Science & Practice Perspectives, 1(1), 13\u201320.","journal-title":"Science & Practice Perspectives"},{"issue":"4","key":"1056_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jval.2017.07.014","volume":"21","author":"S Langham","year":"2018","unstructured":"Langham, S., Wright, A., Kenworthy, J., Grieve, R., & Dunlop, W. C. N. (2018). Cost-effectiveness of take-home naloxone for the prevention of overdose fatalities among heroin users in the United Kingdom. Value in Health, 21(4), 407\u2013415. https:\/\/doi.org\/10.1016\/j.jval.2017.07.014","journal-title":"Value in Health"},{"key":"1056_CR22","doi-asserted-by":"publisher","unstructured":"Nielsen, S., Larance, B., Degenhardt, L., Gowing, L., Kehler, C., & Lintzeris, N. (2016). Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database of Systematic Reviews, 2016 (5). John Wiley and Sons Ltd. https:\/\/doi.org\/10.1002\/14651858.CD011117.pub2","DOI":"10.1002\/14651858.CD011117.pub2"},{"issue":"3","key":"1056_CR23","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/add.13668","volume":"112","author":"MKB Parmar","year":"2017","unstructured":"Parmar, M. K. B., Strang, J., Choo, L., Meade, A. M., & Bird, S. M. (2017). Randomized controlled pilot trial of naloxone-on-release to prevent post-prison opioid overdose deaths. Addiction, 112(3), 502\u2013515. https:\/\/doi.org\/10.1111\/add.13668","journal-title":"Addiction"},{"issue":"5","key":"1056_CR24","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","volume":"103","author":"RP Schwartz","year":"2013","unstructured":"Schwartz, R. P., Gryczynski, J., O\u2019Grady, K. E., Sharfstein, J. M., Warren, G., Olsen, Y., Mitchell, S. G., & Jaffe, J. H. (2013). Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995\u20132009. American Journal of Public Health, 103(5), 917\u2013922. https:\/\/doi.org\/10.2105\/AJPH.2012.301049","journal-title":"American Journal of Public Health"},{"key":"1056_CR25","unstructured":"streetRx. (2021). Canadian latest street prices for prescription drugs. https:\/\/streetrx.com\/ca\/en"},{"key":"1056_CR26","doi-asserted-by":"publisher","unstructured":"Sullivan, L. E., Metzger, D. S., Fudala, P. J., & Fiellin, D. A. (2005). Decreasing international HIV transmission: The role of expanding access to opioid agonist therapies for injection drug users. Addiction, 100 (2), 150\u2013158. John Wiley & Sons, Ltd. https:\/\/doi.org\/10.1111\/j.1360-0443.2004.00963.x","DOI":"10.1111\/j.1360-0443.2004.00963.x"},{"issue":"2","key":"1056_CR27","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1016\/S2214-109X(16)30303-5","volume":"5","author":"MP Wegman","year":"2017","unstructured":"Wegman, M. P., Altice, F. L., Kaur, S., Rajandaran, V., Osornprasop, S., Wilson, D., Wilson, D. P., & Kamarulzaman, A. (2017). Relapse to opioid use in opioid-dependent individuals released from compulsory drug detention centres compared with those from voluntary methadone treatment centres in Malaysia: A two-arm, prospective observational study. The Lancet Global Health, 5(2), e198\u2013e207. https:\/\/doi.org\/10.1016\/S2214-109X(16)30303-5","journal-title":"The Lancet Global Health"},{"key":"1056_CR28","unstructured":"World Health Organization. (2014). Community management of opioid overdose. https:\/\/www.who.int\/publications\/i\/item\/9789241548816"}],"container-title":["Canadian Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.17269\/s41997-025-01056-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.17269\/s41997-025-01056-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.17269\/s41997-025-01056-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T22:02:53Z","timestamp":1763503373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.17269\/s41997-025-01056-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1056"],"URL":"https:\/\/doi.org\/10.17269\/s41997-025-01056-y","relation":{},"ISSN":["0008-4263","1920-7476"],"issn-type":[{"type":"print","value":"0008-4263"},{"type":"electronic","value":"1920-7476"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was received from the Conjoint Health Research Ethics Board, University of Calgary (Ethics ID: 180024).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Woroniuk is the Director of the Community Based Naloxone Program. The remaining authors have no conflicts of interest to report.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}